Homocysteine as atherothrombotic agent: Is the bark worse than the bite?

Nutrition

Volumn 16, Issue 7-8, 2000, Pages 672-674

  Ubbink, Johan B ^a   Delport, Rhena ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; FOLIC ACID; HOMOCYSTEINE;

AMINO ACID METABOLISM; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; HUMAN; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; THROMBOGENESIS;

ARTERIOSCLEROSIS; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; RISK FACTORS; THROMBOSIS;

EID: 0034235724     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0899-9007(00)00356-7     Document Type: Conference Paper

References (40)

1. Clarke R., Daly L., Robinson K., et al. Hyperhomocysteinemia an independent risk factor for vascular disease . N Engl J Med. 324:1991;1149.
2. Selhub J., Jacques P.F., Bostom A.G., et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 332:1995;286.
3. Steegers-Theunissen R.P.M., Boers G.H.J., Trijbels F.J.M., et al. Maternal hyperhomocysteinemia a risk factor for neural-tube defects? Metabolism. 43:1994;1475.
4. Mills J.L., McPartlin J.M., Kirke P.N., et al. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet. 345:1995;149.
5. Gibson J.B., Carson N.A.J., Neill D.W. Pathological findings in homocystinuria. J Clin Path. 17:1964;427.
6. McCully K.S. Vascular pathology of homocysteinemia implications for the pathogenesis of arteriosclerosis . Am J Pathol. 56:1969;111.
7. Kanwar Y.S., Manaligod J.R., Wong P.W.K. Morphologic studies in a patient with homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency. Pediatr Res. 10:1976;598.
8. Van der Put N.M.J., Steegers-Theunissen R.P.M., Frosst P., et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet. 346:1995;1070.
9. Kang S.S., Passen E.L., Ruggie N., Wong P.W.K., Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 88:1993;1463.
10. Stipanuk M.H. Metabolism of sulfur-containing amino acids. Annu Rev Nutr. 6:1986;179.
11. Christensen B., Refsum H., Vintermyr O., Ueland P.M. Homocysteine export from cells cultured in the presence of physiological or superfluous levels of methionine methionine loading of non-transformed, transformed, proliferating, and quiescent cells in culture . J Cell Physiol. 146:1991;52.
12. Kang S., Zhou J., Wong P.W.K., Kowalisyn J., Strokosch G. Intermediate homocysteinemia a thermolabile variant of methylenetetrahydrofolate reductase . Am J Hum Genet. 43:1988;414.
13. Goyette P., Sumner J.S., Milos R., et al. Human methylene tetrahydrofolate reductase isolation of cDNA, mapping and mutation identification . Nat Genet. 7:1994;195.
14. Jacques P.F., Bostom A.G., Williams R.R., et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase and plasma homocysteine concentrations. Circulation. 93:1996;7.
15. Arruda V.R., von Zuben P.M., Chiaparini L.C., Annichino-Bizzachi J.M., Costa F.F. The mutation Ala677-Val in the methylenetetrahydrofolate reductase gene a risk factor for arterial disease and venous thrombosis . Thromb Haem. 11:1997;818.
16. Gallagher P.M., Meleady R., Shields D.C., et al. Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. Circulation. 94:1996;2154.
17. Deloughery T.G., Evans A., Sadeghi A., et al. Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease. Circulation. 94:1996;3074.
18. Wilcken D.E.L., Wang X.L., Wilcken B. Methylenetetrahydrofolate reductase (MTHFR) mutation, homocyst(e)ine, and coronary artery disease. Circulation. 96:1997;2738.
19. Allen R.H., Stabler S.P., Savage D.G., Lindenbaum J. Metabolic abnormalities in cobalamin (vitamin B-12) and folate deficiency. FASEB J. 7:1993;1344.
20. Ubbink J.B., Vermaak W.J.H., Van der Merwe A., et al. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr. 124:1994;1927.
21. 6 status on homocysteine metabolism. J Clin Invest. 98:1996;177.
22. Tawakol A., Omland T., Gerhard M., Wu J.T., Creager M.A. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation. 95:1997;1119.
23. Tsai J.-C., Perrella M.A., Yoshizumi M., et al. Promotion of vascular smooth muscle cell growth by homocysteine a link to atherosclerosis . Proc Natl Acad Sci USA. 91:1994;6369.
24. Heinecke J.W., Rosen H., Suzuji L.A., Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low-density lipoprotein by arterial smooth muscle cells. J Biol Chem. 262:1987;10098.
25. Rodgers G.M., Kane W.H. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest. 77:1986;1909.
26. Lentz S.R., Sadler J.E. Inhibition of the thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest. 88:1991;1906.
27. Hajjar K. Homocysteine-induced modulation if tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest. 91:1993;2873.
28. a-catalyzed prothrombin activation. J Clin Invest. 81:1988;1911.
29. Malinow M.R., Nieto J., Szklo M., Chambless L.E., Bond G. Carotid artery intimal-medial wall thickening and plasma homocysteine in asymptomatic adults. Circulation. 87:1993;1107.
30. Boushey C.J., Beresford S.A.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA. 274:1995;1049.
31. Hill A.B. The environment and disease association or causation? Proc R Soc Med. 58:1965;295.
32. Stampfer M.J., Malinow R., Willet W.C., et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 268:1992;877.
33. Arnesen E., Refsum H., Bonaa K.H., et al. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 24:1995;704.
34. Wald N.J., Watt H.C., Law M.R., et al. Homocysteine, and ischemic heart disease. Results of a prospective study with implications regarding prevention. Arch Intern Med. 158:1998;862.
35. Alfthan G., Pekkanen J., Jauhiainen M., et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 106:1994;9.
36. Evans R.W., Shaten B.J., Hempel J.D., Cutler J.A., Kuller L.H. Homocyst(e)ine and risk of cardiovascular disease in the multiple risk factor intervention trial. Arterioscler Thromb Vasc Biol. 17:1997;1947.
37. Ubbink J.B., Fehily A.M., Pickering J., Elwood P.C., Vermaak W.J.H. Homocysteine and ischaemic heart disease in the Caerphilly cohort. Atherosclerosis. 140:1998;349.
38. Nygård O., Nordrehaug J.E., Refsum H., et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 337:1997;230.
39. Garg U.C., Zheng Z.J., Folsom A.R., et al. Short-term and long-term variability of plasma homocysteine measurement. Clin Chem. 43:1997;141.
40. Hankey G.J., Eikelboom J.W. Homocysteine and vascular disease. Lancet. 354:1999;407.